In 2018, the Rao group pioneered the development of a PROTAC molecule, designated as compound 3, which was shown to induce PARP1 cleavage and cell apoptosis in the MDA-MB-231 breast cancer cell line [38]. This evidence concerns the gene PARP1 and breast carcinoma.